As the world’s largest medical association of musculoskeletal specialists, AAOS announced in November 2019 a strategic investment in the field of biologics and future disruptive technologies. Over the next five years, AAOS will prioritize research and development for a biologics-focused competency addressing issues of unreliable information and patient receipt of substandard care from nonorthopaedists, as well as continuing to be the trustworthy source of information for patients, members, and external providers and payers. This reprioritization is an expansion of previous work of many members on previous committees who also worked in this space.
> Read more
